troglitazone has been researched along with Diabetes Mellitus in 79 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
Diabetes Mellitus: A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Studies and abstracts chosen summarize the clinical action of troglitazone in healthy volunteers, in subjects with impaired glucose tolerance, and in patients with diabetes mellitus." | 8.80 | Troglitazone: review and assessment of its role in the treatment of patients with impaired glucose tolerance and diabetes mellitus. ( Campbell, LK; Campbell, RK; Johnson, MD, 1998) |
| " Therapy was directed primarily at decreasing insulin resistance and thereby improving glucose intolerance by the administration of troglitazone, which increases insulin sensitivity." | 7.70 | Troglitazone ameliorates insulin resistance in a diabetic patient with Prader-Willi syndrome. ( Fujii, S; Fujita, K; Ishii, T; Kurimasa, H; Mori, T; Sato, T; Tanaka, S; Yamakita, T; Yoshioka, K, 1998) |
| "Seventy-eight patients with type 2 diabetes adequately controlled with glibenclamide were randomly allocated to a troglitazone (400 mg/d)-added group (n = 40) or a control group without placebo (n = 38) and monitored for 24 weeks." | 6.70 | Troglitazone prevents the rise in visceral adiposity and improves fatty liver associated with sulfonylurea therapy--a randomized controlled trial. ( Hata, S; Ikemoto, S; Inoue, Y; Katoh, S; Matsushima, M; Tajima, N; Yokoyama, J, 2001) |
| "Treatment with troglitazone 400 mg q." | 6.69 | Effects of troglitazone on insulin sensitivity in HIV-infected patients with protease inhibitor-associated diabetes mellitus. ( Brinkmann, L; Goebel, FD; Michl, GM; Mühlbayer, D; Walli, R, 2000) |
| "This troglitazone-induced increase in the expression of aP2 and FAT/CD36 was markedly enhanced in the liver in ob/ob mice." | 5.31 | Up-regulation of peroxisome proliferator-activated receptors (PPAR-alpha) and PPAR-gamma messenger ribonucleic acid expression in the liver in murine obesity: troglitazone induces expression of PPAR-gamma-responsive adipose tissue-specific genes in the li ( Beigneux, A; Feingold, KR; Grunfeld, C; Memon, RA; Moser, AH; Nonogaki, K; Tecott, LH, 2000) |
| "Troglitazone has been shown to improve peripheral insulin resistance in type 2 diabetic patients and animal models." | 5.31 | Troglitazone improves GLUT4 expression in adipose tissue in an animal model of obese type 2 diabetes mellitus. ( Adachi, Y; Araki-Sasaki, R; Furuta, M; Gabazza, EC; Hori, Y; Katsuki, A; Nakatani, K; Sumida, Y; Tanaka, T; Yano, Y, 2002) |
| " Studies and abstracts chosen summarize the clinical action of troglitazone in healthy volunteers, in subjects with impaired glucose tolerance, and in patients with diabetes mellitus." | 4.80 | Troglitazone: review and assessment of its role in the treatment of patients with impaired glucose tolerance and diabetes mellitus. ( Campbell, LK; Campbell, RK; Johnson, MD, 1998) |
| " Metformin and troglitazone, approved for use in the treatment of type 2 diabetes mellitus (DM), improve insulin sensitivity and lower plasma glucose concentrations." | 4.80 | Insulin resistance syndrome: options for treatment. ( Fonseca, VA; Granberry, MC, 1999) |
| "Troglitazone decreases insulin resistance (improves insulin sensitivity), which results in reduced plasma glucose and insulin levels in patients with non-insulin-dependent diabetes mellitus (NIDDM)." | 4.79 | Troglitazone. ( Markham, A; Spencer, CM, 1997) |
| " Therapy was directed primarily at decreasing insulin resistance and thereby improving glucose intolerance by the administration of troglitazone, which increases insulin sensitivity." | 3.70 | Troglitazone ameliorates insulin resistance in a diabetic patient with Prader-Willi syndrome. ( Fujii, S; Fujita, K; Ishii, T; Kurimasa, H; Mori, T; Sato, T; Tanaka, S; Yamakita, T; Yoshioka, K, 1998) |
| "We found that increasing dosage of the C risk allele at SLC30A8 rs13266634 was significantly associated with higher proinsulin levels at baseline (p = 0." | 2.76 | Association of the SLC30A8 missense polymorphism R325W with proinsulin levels at baseline and after lifestyle, metformin or troglitazone intervention in the Diabetes Prevention Program. ( Florez, JC; Goldberg, RB; Jablonski, KA; Kahn, SE; Majithia, AR; Mather, KJ; McAteer, JB, 2011) |
| "Troglitazone treatment increased serum adiponectin levels nearly threefold." | 2.71 | Modulation of circulating and adipose tissue adiponectin levels by antidiabetic therapy. ( Aroda, V; Bandukwala, R; Baxi, S; Carter, L; Ciaraldi, TP; Henry, RR; Kong, AP; Mudaliar, SR; Phillips, SA, 2003) |
| "Seventy-eight patients with type 2 diabetes adequately controlled with glibenclamide were randomly allocated to a troglitazone (400 mg/d)-added group (n = 40) or a control group without placebo (n = 38) and monitored for 24 weeks." | 2.70 | Troglitazone prevents the rise in visceral adiposity and improves fatty liver associated with sulfonylurea therapy--a randomized controlled trial. ( Hata, S; Ikemoto, S; Inoue, Y; Katoh, S; Matsushima, M; Tajima, N; Yokoyama, J, 2001) |
| "Seven obese patients with type 2 diabetes were treated with troglitazone (400 mg/day) for 4 weeks." | 2.70 | Nuclear factor-kappaB suppressive and inhibitor-kappaB stimulatory effects of troglitazone in obese patients with type 2 diabetes: evidence of an antiinflammatory action? ( Aljada, A; Assian, E; Dandona, P; Garg, R; Ghanim, H; Hamouda, W; Mohanty, P, 2001) |
| "Treatment with troglitazone 400 mg q." | 2.69 | Effects of troglitazone on insulin sensitivity in HIV-infected patients with protease inhibitor-associated diabetes mellitus. ( Brinkmann, L; Goebel, FD; Michl, GM; Mühlbayer, D; Walli, R, 2000) |
| " Long-term administration of the drug resulted in weight gain with increased accumulation of SC adipose tissue, probably because of the activation of PPAR-gamma in the region." | 2.69 | Efficacy of troglitazone on body fat distribution in type 2 diabetes. ( Akazawa, S; Eguchi, K; Ito, M; Kawasaki, E; Sun, F, 2000) |
| "The prevalence of type 2 diabetes is increasing due to a combination of factors: increasing lifespan, sedentary lifestyle, excessive intake of high energy foods, increasing prevalence of overweight/obese people." | 2.41 | Prevention of type 2 diabetes. ( Lai, LC, 2002) |
| "Diabetes mellitus is associated with alterations in a number of key metabolic pathways." | 2.40 | Drug administration in patients with diabetes mellitus. Safety considerations. ( Cooper, ME; Gilbert, RE; Krum, H, 1998) |
| "Troglitazone is a new oral insulin-sensitizing agent from the thiazolidinedione group of compounds that has been developed in Japan Thiazolidinediones improve the insulin sensitivity at muscle, adipose tissue and liver." | 2.40 | [Insulin-sensitizing agent]. ( Yamanouchi, T, 1999) |
| " In summary, our data from cell culture and wound healing experiments suggested p38 MAPK activation as a side effect of thiazolidinediones; however, only troglitazone, but not rosiglitazone, seemed to translate p38 MAPK activation into a PPARgamma-independent induction of VEGF from keratinocytes." | 1.35 | Keratinocyte-derived vascular endothelial growth factor biosynthesis represents a pleiotropic side effect of peroxisome proliferator-activated receptor-gamma agonist troglitazone but not rosiglitazone and involves activation of p38 mitogen-activated prote ( Bachmann, M; Dissmann, JP; Frank, S; Geisslinger, G; Goren, I; Pfeilschifter, J; Sader, R; Schiefelbein, D; Schmidt, H; Seitz, O, 2008) |
| "Troglitazone was administered to OLETF rats to examine the effect of the drug on the changes in PTPase activity and distribution." | 1.31 | Troglitazone ameliorates abnormal activity of protein tyrosine phosphatase in adipose tissues of Otsuka Long-Evans Tokushima Fatty rats. ( Homma, H; Honda, T; Ide, H; Kawakami, Y; Ohno, K; Sakaue, S; Tagami, S; Yoshimura, H, 2002) |
| "ZDF rats developed diabetic osteopenia with reduced bone turnover, and this was prevented by JTT-501 and troglitazone, possibly mediated by increased bone turnover and bone formation." | 1.31 | Effects of peroxisome proliferator-activated receptor-alpha and -gamma agonist, JTT-501, on diabetic complications in Zucker diabetic fatty rats. ( Kakimoto, K; Shibata, T; Takeuchi, S; Wakitani, K; Yokota, S; Yonemori, F, 2000) |
| "Troglitazone is a CYP3A4 isoenzyme inducer known to decrease the plasma concentration of drugs metabolized by CYP3A4." | 1.31 | Potential interaction between troglitazone and atorvastatin. ( DiTusa, L; Luzier, AB, 2000) |
| "Troglitazone has been shown to improve insulin sensitivity and thereby exert hypoglycemic effects in various animal models and humans with insulin resistance and diabetes." | 1.31 | Troglitazone prevents and reverses dyslipidemia, insulin secretory defects, and histologic abnormalities in a rat model of naturally occurring obese diabetes. ( Akiyama, T; Fukumitsu, KI; Jia, DM; Nakamura, H; Otsuki, M; Tabaru, A, 2000) |
| "This troglitazone-induced increase in the expression of aP2 and FAT/CD36 was markedly enhanced in the liver in ob/ob mice." | 1.31 | Up-regulation of peroxisome proliferator-activated receptors (PPAR-alpha) and PPAR-gamma messenger ribonucleic acid expression in the liver in murine obesity: troglitazone induces expression of PPAR-gamma-responsive adipose tissue-specific genes in the li ( Beigneux, A; Feingold, KR; Grunfeld, C; Memon, RA; Moser, AH; Nonogaki, K; Tecott, LH, 2000) |
| "Dyslipoproteinemia associated with type 2 diabetes comprises hypertriglyceridemia caused by reduced insulin sensitivity, and consequently, low HDL levels and an increase in the proportion of small dense LDL particles." | 1.31 | [Diabetic dyslipoproteinemia: physiopathological bases and treatment prospects]. ( Demant, T, 2001) |
| "Troglitazone has been shown to improve peripheral insulin resistance in type 2 diabetic patients and animal models." | 1.31 | Troglitazone improves GLUT4 expression in adipose tissue in an animal model of obese type 2 diabetes mellitus. ( Adachi, Y; Araki-Sasaki, R; Furuta, M; Gabazza, EC; Hori, Y; Katsuki, A; Nakatani, K; Sumida, Y; Tanaka, T; Yano, Y, 2002) |
| " Dose-response relationships for both of the TZDs were also determined using the 24-h treatment time point." | 1.30 | A novel method for analysis of nuclear receptor function at natural promoters: peroxisome proliferator-activated receptor gamma agonist actions on aP2 gene expression detected using branched DNA messenger RNA quantitation. ( Burris, TP; Cryan, E; Demarest, KT; Osborne, MC; Pelton, PD; Zhou, L, 1999) |
| "Troglitazone was administered for 7 days to normal ddY mice, diabetic KK mice, diabetic C57BL/KsJ-db/db mice, and its heterozygote, db/+ mice, as a 0." | 1.29 | Suppression of hepatic gluconeogenesis in long-term Troglitazone treated diabetic KK and C57BL/KsJ-db/db mice. ( Fujiwara, T; Horikoshi, H; Okuno, A; Yoshioka, S, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 32 (40.51) | 18.2507 |
| 2000's | 40 (50.63) | 29.6817 |
| 2010's | 6 (7.59) | 24.3611 |
| 2020's | 1 (1.27) | 2.80 |
| Authors | Studies |
|---|---|
| Berger, J | 1 |
| Bailey, P | 1 |
| Biswas, C | 1 |
| Cullinan, CA | 1 |
| Doebber, TW | 1 |
| Hayes, NS | 1 |
| Saperstein, R | 1 |
| Smith, RG | 1 |
| Leibowitz, MD | 1 |
| Willson, TM | 1 |
| Brown, PJ | 1 |
| Sternbach, DD | 1 |
| Henke, BR | 1 |
| Brooks, DA | 1 |
| Etgen, GJ | 1 |
| Rito, CJ | 1 |
| Shuker, AJ | 1 |
| Dominianni, SJ | 1 |
| Warshawsky, AM | 1 |
| Ardecky, R | 1 |
| Paterniti, JR | 1 |
| Tyhonas, J | 1 |
| Karanewsky, DS | 1 |
| Kauffman, RF | 1 |
| Broderick, CL | 1 |
| Oldham, BA | 1 |
| Montrose-Rafizadeh, C | 1 |
| Winneroski, LL | 1 |
| Faul, MM | 1 |
| McCarthy, JR | 1 |
| Lin, HR | 1 |
| Dirven, H | 1 |
| Vist, GE | 1 |
| Bandhakavi, S | 1 |
| Mehta, J | 1 |
| Fitch, SE | 1 |
| Pound, P | 1 |
| Ram, R | 1 |
| Kincaid, B | 1 |
| Leenaars, CHC | 1 |
| Chen, M | 1 |
| Wright, RA | 1 |
| Tsaioun, K | 1 |
| Tsujino, Y | 1 |
| Della-Morte, D | 1 |
| Palmirotta, R | 1 |
| Rehni, AK | 1 |
| Pastore, D | 1 |
| Capuani, B | 1 |
| Pacifici, F | 1 |
| De Marchis, ML | 1 |
| Dave, KR | 1 |
| Bellia, A | 1 |
| Fogliame, G | 1 |
| Ferroni, P | 1 |
| Donadel, G | 1 |
| Cacciatore, F | 1 |
| Abete, P | 1 |
| Dong, C | 1 |
| Pileggi, A | 1 |
| Roselli, M | 1 |
| Ricordi, C | 1 |
| Sbraccia, P | 1 |
| Guadagni, F | 1 |
| Rundek, T | 1 |
| Lauro, D | 1 |
| He, J | 1 |
| Xu, C | 1 |
| Kuang, J | 1 |
| Liu, Q | 1 |
| Jiang, H | 1 |
| Mo, L | 1 |
| Geng, B | 1 |
| Xu, G | 1 |
| Schiefelbein, D | 1 |
| Seitz, O | 1 |
| Goren, I | 1 |
| Dissmann, JP | 1 |
| Schmidt, H | 1 |
| Bachmann, M | 1 |
| Sader, R | 1 |
| Geisslinger, G | 1 |
| Pfeilschifter, J | 1 |
| Frank, S | 1 |
| Gale, EA | 1 |
| Majithia, AR | 1 |
| Jablonski, KA | 1 |
| McAteer, JB | 1 |
| Mather, KJ | 1 |
| Goldberg, RB | 1 |
| Kahn, SE | 1 |
| Florez, JC | 1 |
| Tagami, S | 1 |
| Honda, T | 1 |
| Yoshimura, H | 1 |
| Homma, H | 1 |
| Ohno, K | 1 |
| Ide, H | 1 |
| Sakaue, S | 1 |
| Kawakami, Y | 1 |
| Raji, A | 1 |
| Plutzky, J | 1 |
| Solignac, M | 1 |
| Phillips, SA | 1 |
| Ciaraldi, TP | 2 |
| Kong, AP | 1 |
| Bandukwala, R | 1 |
| Aroda, V | 1 |
| Carter, L | 1 |
| Baxi, S | 1 |
| Mudaliar, SR | 1 |
| Henry, RR | 2 |
| Sekino, N | 1 |
| Kashiwabara, A | 1 |
| Inoue, T | 1 |
| Kawasaki, T | 1 |
| Ogata, N | 1 |
| Sawashige, K | 1 |
| Yamanouchi, T | 2 |
| Angulo, P | 1 |
| Muniyappa, R | 1 |
| El-Atat, F | 1 |
| Aneja, A | 1 |
| McFarlane, SI | 1 |
| Lai, LC | 1 |
| Graham, DJ | 1 |
| Wang, MY | 1 |
| Unger, RH | 3 |
| Reamy, BV | 1 |
| Izzedine, H | 1 |
| Launay-Vacher, V | 1 |
| Buhaescu, I | 1 |
| Heurtier, A | 1 |
| Baumelou, A | 1 |
| Deray, G | 1 |
| Campbell, IW | 1 |
| Mariz, S | 1 |
| Sell, H | 1 |
| Eckel, J | 1 |
| Yoshikawa, M | 1 |
| Wang, T | 1 |
| Morikawa, T | 1 |
| Xie, H | 1 |
| Matsuda, H | 1 |
| Fujiwara, T | 3 |
| Okuno, A | 1 |
| Yoshioka, S | 2 |
| Horikoshi, H | 3 |
| Cominacini, L | 1 |
| Garbin, U | 1 |
| Pastorino, AM | 1 |
| Campagnola, M | 1 |
| Fratta Pasini, A | 1 |
| Davoli, A | 1 |
| Rigoni, A | 1 |
| Lo Cascio, V | 1 |
| Sakane, N | 1 |
| Yoshida, T | 1 |
| Kondo, M | 1 |
| Hirose, T | 1 |
| Kurebayashi, S | 1 |
| Spencer, CM | 1 |
| Markham, A | 1 |
| Bloomgarden, ZT | 1 |
| Hehenberger, K | 1 |
| Hansson, A | 1 |
| Arakawa, K | 1 |
| Inamasu, M | 1 |
| Matsumoto, M | 1 |
| Okumura, K | 1 |
| Yasuda, K | 1 |
| Akatsuka, H | 1 |
| Kawanami, S | 1 |
| Watanabe, A | 1 |
| Homma, K | 1 |
| Saiga, Y | 1 |
| Ozeki, M | 1 |
| Iijima, I | 1 |
| Wise, J | 1 |
| Shimabukuro, M | 1 |
| Zhou, YT | 2 |
| Levi, M | 1 |
| Watkins, PB | 1 |
| Whitcomb, RW | 1 |
| Johnson, MD | 1 |
| Campbell, LK | 1 |
| Campbell, RK | 1 |
| Park, KS | 1 |
| Abrams-Carter, L | 1 |
| Mudaliar, S | 1 |
| Nikoulina, SE | 1 |
| Plowman, BK | 1 |
| Morreale, AP | 1 |
| Bachman, KH | 1 |
| Gilbert, RE | 1 |
| Cooper, ME | 1 |
| Krum, H | 1 |
| Bell, DS | 1 |
| Ovalle, F | 1 |
| Yamakita, T | 1 |
| Ishii, T | 1 |
| Mori, T | 1 |
| Yoshioka, K | 1 |
| Sato, T | 1 |
| Tanaka, S | 1 |
| Kurimasa, H | 1 |
| Fujita, K | 1 |
| Fujii, S | 1 |
| Granberry, MC | 1 |
| Fonseca, VA | 1 |
| Burris, TP | 1 |
| Pelton, PD | 1 |
| Zhou, L | 1 |
| Osborne, MC | 1 |
| Cryan, E | 1 |
| Demarest, KT | 1 |
| Kobayashi, J | 1 |
| Nagashima, I | 1 |
| Hikita, M | 1 |
| Bujo, H | 1 |
| Takahashi, K | 1 |
| Otabe, M | 1 |
| Morisaki, N | 1 |
| Saito, Y | 1 |
| Aoki, K | 2 |
| Saito, T | 2 |
| Satoh, S | 2 |
| Mukasa, K | 2 |
| Kaneshiro, M | 1 |
| Kawasaki, S | 1 |
| Okamura, A | 2 |
| Sekihara, H | 2 |
| Higa, M | 1 |
| Ravazzola, M | 1 |
| Baetens, D | 1 |
| Orci, L | 1 |
| Tack, CJ | 1 |
| Smits, P | 1 |
| DeMacker, PN | 1 |
| Stalenhoef, AF | 1 |
| Fujibayashi, K | 1 |
| Nagasaka, S | 1 |
| Itabashi, N | 1 |
| Kawakami, A | 1 |
| Nakamura, T | 1 |
| Kusaka, I | 1 |
| Ishikawa, S | 1 |
| Mozersky, RP | 1 |
| Ide, T | 1 |
| Nakazawa, T | 1 |
| Mochizuki, T | 1 |
| Murakami, K | 1 |
| Walli, R | 1 |
| Michl, GM | 1 |
| Mühlbayer, D | 1 |
| Brinkmann, L | 1 |
| Goebel, FD | 1 |
| Shibata, T | 1 |
| Takeuchi, S | 1 |
| Yokota, S | 1 |
| Kakimoto, K | 1 |
| Yonemori, F | 1 |
| Wakitani, K | 1 |
| Frias, JP | 1 |
| Yu, JG | 1 |
| Kruszynska, YT | 1 |
| Olefsky, JM | 1 |
| Reddy, SS | 1 |
| Akazawa, S | 1 |
| Sun, F | 1 |
| Ito, M | 1 |
| Kawasaki, E | 1 |
| Eguchi, K | 1 |
| DiTusa, L | 1 |
| Luzier, AB | 1 |
| Jia, DM | 1 |
| Tabaru, A | 1 |
| Nakamura, H | 1 |
| Fukumitsu, KI | 1 |
| Akiyama, T | 1 |
| Otsuki, M | 1 |
| Memon, RA | 1 |
| Tecott, LH | 1 |
| Nonogaki, K | 1 |
| Beigneux, A | 1 |
| Moser, AH | 1 |
| Grunfeld, C | 1 |
| Feingold, KR | 1 |
| Carlton, FB | 1 |
| Katsuki, A | 2 |
| Sumida, Y | 2 |
| Murata, K | 1 |
| Furuta, M | 2 |
| Araki-Sasaki, R | 2 |
| Tsuchihashi, K | 1 |
| Hori, Y | 2 |
| Yano, Y | 2 |
| Gabazza, EC | 2 |
| Adachi, Y | 2 |
| Kikuchi, T | 1 |
| Ito, S | 1 |
| Nakajima, A | 1 |
| Katoh, S | 1 |
| Hata, S | 1 |
| Matsushima, M | 1 |
| Ikemoto, S | 1 |
| Inoue, Y | 1 |
| Yokoyama, J | 1 |
| Tajima, N | 1 |
| Maher, J | 1 |
| Harano, Y | 1 |
| Aljada, A | 1 |
| Garg, R | 1 |
| Ghanim, H | 1 |
| Mohanty, P | 1 |
| Hamouda, W | 1 |
| Assian, E | 1 |
| Dandona, P | 1 |
| Bedoucha, M | 1 |
| Atzpodien, E | 1 |
| Boelsterli, UA | 1 |
| Hayashi, H | 1 |
| Sato, Y | 1 |
| Kanai, S | 1 |
| Ichikawa, M | 1 |
| Funakoshi, A | 1 |
| Miyasaka, K | 1 |
| Montague, CT | 1 |
| Demant, T | 1 |
| Bonnefont-Rousselot, D | 1 |
| Tanaka, T | 1 |
| Nakatani, K | 1 |
| Wada, M | 1 |
| Fukuda, K | 1 |
| Fukami, M | 1 |
| Yoshioka, T | 1 |
18 reviews available for troglitazone and Diabetes Mellitus
| Article | Year |
|---|---|
The PPARs: from orphan receptors to drug discovery.
Topics: Animals; Diabetes Mellitus; Drug Design; Humans; Hyperlipidemias; Hypertension; Inflammation; Ligand | 2000 |
Performance of preclinical models in predicting drug-induced liver injury in humans: a systematic review.
Topics: Chemical and Drug Induced Liver Injury; Diabetes Mellitus; Drug-Related Side Effects and Adverse Rea | 2021 |
Pharmacogenomics and pharmacogenetics of thiazolidinediones: role in diabetes and cardiovascular risk factors.
Topics: Cardiovascular Diseases; Chromans; Diabetes Mellitus; Humans; Pharmacogenetics; Pioglitazone; Precis | 2014 |
Insulin resistance, diabetes, and atherosclerosis: thiazolidinediones as therapeutic interventions.
Topics: Adipose Tissue; Animals; Chromans; Coronary Artery Disease; Diabetes Mellitus; Diabetic Angiopathies | 2002 |
Current best treatment for non-alcoholic fatty liver disease.
Topics: Antioxidants; Chromans; Clinical Trials as Topic; Diabetes Complications; Diabetes Mellitus; Fatty L | 2003 |
Prevention of type 2 diabetes.
Topics: Acarbose; Chromans; Diabetes Mellitus; Diabetes Mellitus, Type 2; Exercise; Female; Humans; Hypoglyc | 2002 |
PPAR-gamma-agonists' renal effects.
Topics: Animals; Chromans; Diabetes Mellitus; Hemodynamics; Humans; Hypoglycemic Agents; Kidney; PPAR gamma; | 2005 |
Beta-cell preservation with thiazolidinediones.
Topics: Chromans; Diabetes Mellitus; Humans; Insulin; Insulin Secretion; Insulin-Secreting Cells; Pioglitazo | 2007 |
[Adipocyte differentiation and nuclear receptor].
Topics: Adipocytes; Cell Differentiation; Chromans; Diabetes Mellitus; Humans; Hypoglycemic Agents; Insulin | 1997 |
Troglitazone.
Topics: Animals; Chromans; Diabetes Mellitus; Humans; Hypoglycemic Agents; Thiazoles; Thiazolidinediones; Tr | 1997 |
[Troglitazone: its pharmacology and mechanism of action].
Topics: Animals; Chromans; Diabetes Mellitus; Disease Models, Animal; Glycogen; Glycolysis; Humans; Hypoglyc | 1997 |
Troglitazone: review and assessment of its role in the treatment of patients with impaired glucose tolerance and diabetes mellitus.
Topics: Animals; Chromans; Clinical Trials as Topic; Diabetes Mellitus; Glucose Intolerance; Humans; Hypogly | 1998 |
Drug administration in patients with diabetes mellitus. Safety considerations.
Topics: Acarbose; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Ag | 1998 |
Insulin resistance syndrome: options for treatment.
Topics: Arteriosclerosis; Chromans; Diabetes Mellitus; Diabetes Mellitus, Type 2; Female; Humans; Hyperlipid | 1999 |
[Insulin-sensitizing agent].
Topics: Chromans; Diabetes Mellitus; Humans; Hypoglycemic Agents; Thiazoles; Thiazolidinediones; Troglitazon | 1999 |
Recent advances in the pharmacologic management of diabetes mellitus.
Topics: Acarbose; Administration, Oral; Carbamates; Chromans; Diabetes Mellitus; Drug Overdose; Emergencies; | 2000 |
[Lipodystrophia].
Topics: Animals; Cardiomyopathy, Hypertrophic; Chromans; Diabetes Mellitus; Diagnosis, Differential; Fatty L | 2001 |
[Antioxidant and anti-AGE therapeutics: evaluation and perspectives].
Topics: Antioxidants; Chromans; Diabetes Mellitus; Gliclazide; Glycation End Products, Advanced; Guanidines; | 2001 |
11 trials available for troglitazone and Diabetes Mellitus
| Article | Year |
|---|---|
Association of the SLC30A8 missense polymorphism R325W with proinsulin levels at baseline and after lifestyle, metformin or troglitazone intervention in the Diabetes Prevention Program.
Topics: Adult; C-Peptide; Cation Transport Proteins; Chromans; Diabetes Mellitus; Diabetes Mellitus, Type 2; | 2011 |
Modulation of circulating and adipose tissue adiponectin levels by antidiabetic therapy.
Topics: Adipocytes; Adiponectin; Adipose Tissue; Adult; Aged; Biopsy; Chromans; Culture Media, Conditioned; | 2003 |
Usefulness of troglitazone administration to obese hyperglycaemic patients with near-normoglycaemia.
Topics: Adult; Aged; Blood Glucose; Chromans; Deoxyglucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Fe | 2003 |
The Diabetes Prevention Program.
Topics: Adult; Cardiovascular Diseases; Chromans; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Ang | 2003 |
The Diabetes Prevention Program. Design and methods for a clinical trial in the prevention of type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; Cardiovascular Diseases; Chromans; Diabetes Mellitus; Diabetes Mellitus, | 1999 |
Effect of troglitazone on lipoprotein(a) levels in obese subjects.
Topics: Chromans; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Blind Method; Humans; Hypoglycemic Ag | 1999 |
Effects of troglitazone on insulin sensitivity in HIV-infected patients with protease inhibitor-associated diabetes mellitus.
Topics: Adipose Tissue; Adult; Anti-HIV Agents; Blood Glucose; Body Weight; Chromans; Diabetes Mellitus; HIV | 2000 |
Metabolic effects of troglitazone therapy in type 2 diabetic, obese, and lean normal subjects.
Topics: Adult; Blood Glucose; Body Mass Index; C-Peptide; Cholesterol; Chromans; Diabetes Mellitus; Diabetes | 2000 |
Efficacy of troglitazone on body fat distribution in type 2 diabetes.
Topics: Adipose Tissue; Body Mass Index; C-Peptide; Chromans; Diabetes Mellitus; Diabetes Mellitus, Type 2; | 2000 |
Troglitazone prevents the rise in visceral adiposity and improves fatty liver associated with sulfonylurea therapy--a randomized controlled trial.
Topics: Adipose Tissue; Aged; Chromans; Diabetes Mellitus; Diabetes Mellitus, Type 2; Drug Therapy, Combinat | 2001 |
Nuclear factor-kappaB suppressive and inhibitor-kappaB stimulatory effects of troglitazone in obese patients with type 2 diabetes: evidence of an antiinflammatory action?
Topics: Adult; Anti-Inflammatory Agents; Blood Glucose; C-Reactive Protein; Chemokine CCL2; Cholesterol; Chr | 2001 |
50 other studies available for troglitazone and Diabetes Mellitus
| Article | Year |
|---|---|
Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-gamma: binding and activation correlate with antidiabetic actions in db/db mice.
Topics: Animals; Blood Glucose; COS Cells; Cricetinae; Diabetes Mellitus; Hyperglycemia; Hypertriglyceridemi | 1996 |
Design and synthesis of 2-methyl-2-[4-(2-[5-methyl-2-aryloxazol-4-yl]ethoxy)phenoxy]propionic acids: a new class of dual PPARalpha/gamma agonists.
Topics: Animals; Blood Glucose; Cholesterol, HDL; Diabetes Mellitus; Diabetes Mellitus, Type 2; Drug Design; | 2001 |
Sesquiterpene lactones from Tithonia diversifolia act as peroxisome proliferator-activated receptor agonists.
Topics: Diabetes Mellitus; Drugs, Chinese Herbal; Hep G2 Cells; Humans; Hydrophobic and Hydrophilic Interact | 2012 |
A New Agonist for Peroxisome Proliferation-activated Receptor γ (PPARγ), Fraglide-1 from Zhenjiang Fragrant Vinegar: Screening and Characterization Based on Cell Culture Experiments.
Topics: 4-Butyrolactone; Acetic Acid; Animals; Anti-Obesity Agents; Cells, Cultured; Chlorocebus aethiops; C | 2017 |
Thiazolidinediones attenuate lipolysis and ameliorate dexamethasone-induced insulin resistance.
Topics: Adipocytes; Adipose Tissue; Animals; Chromans; Cyclic AMP; Dexamethasone; Diabetes Mellitus; Fatty A | 2015 |
Keratinocyte-derived vascular endothelial growth factor biosynthesis represents a pleiotropic side effect of peroxisome proliferator-activated receptor-gamma agonist troglitazone but not rosiglitazone and involves activation of p38 mitogen-activated prote
Topics: Animals; Cell Survival; Cells, Cultured; Chromans; Diabetes Mellitus; Dose-Response Relationship, Dr | 2008 |
Therapy: The second time as farce: rosiglitazone and the regulators.
Topics: Chromans; Diabetes Mellitus; Humans; Hypoglycemic Agents; Rosiglitazone; Thiazolidinediones; Troglit | 2011 |
Troglitazone ameliorates abnormal activity of protein tyrosine phosphatase in adipose tissues of Otsuka Long-Evans Tokushima Fatty rats.
Topics: Adipose Tissue; Animals; Cell Fractionation; Chromans; Diabetes Mellitus; Disease Models, Animal; Hy | 2002 |
[News on diabetes and public health perspectives].
Topics: Administration, Oral; Adult; Chromans; Clinical Trials as Topic; Diabetes Mellitus; Diabetes Mellitu | 2002 |
Risk of unexplained acute liver failure in diabetes mellitus.
Topics: Chromans; Diabetes Mellitus; Hepatic Encephalopathy; Humans; Hypoglycemic Agents; Liver Failure, Acu | 2003 |
Role of PP2C in cardiac lipid accumulation in obese rodents and its prevention by troglitazone.
Topics: Adenylate Kinase; Animals; Cells, Cultured; Chromans; Diabetes Mellitus; Fatty Acids, Nonesterified; | 2005 |
Preventing the progression of diabetes mellitus.
Topics: Arteriosclerosis; Chromans; Diabetes Mellitus; Disease Progression; Humans; Hypoglycemic Agents; Inf | 2005 |
Regulation of retinol binding protein 4 production in primary human adipocytes by adiponectin, troglitazone and TNF-alpha.
Topics: Adipocytes; Adiponectin; Chromans; Diabetes Mellitus; Humans; Obesity; Retinol-Binding Proteins, Pla | 2007 |
Bioactive constituents from chinese natural medicines. XXIV. Hypoglycemic effects of Sinocrassula indica in sugar-loaded rats and genetically diabetic KK-A(y) mice and structures of new acylated flavonol glycosides, sinocrassosides A(1), A(2), B(1), and B
Topics: Animals; Blood Glucose; Cholesterol; Chromans; Crassulaceae; Diabetes Mellitus; Fatty Acids, Noneste | 2007 |
Suppression of hepatic gluconeogenesis in long-term Troglitazone treated diabetic KK and C57BL/KsJ-db/db mice.
Topics: Animals; Chromans; Diabetes Mellitus; Fructose-Bisphosphatase; Fructosediphosphates; Gluconeogenesis | 1995 |
Effects of troglitazone on in vitro oxidation of LDL and HDL induced by copper ions and endothelial cells.
Topics: Arteriosclerosis; Cells, Cultured; Chromans; Copper; Diabetes Mellitus; Endothelium; Humans; Hypogly | 1997 |
Glitazones and NIDDM.
Topics: Animals; Chromans; Diabetes Mellitus; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Obesit | 1997 |
Troglitazone for non-insulin-dependent diabetes mellitus.
Topics: Administration, Oral; Chromans; Diabetes Mellitus; Diabetes Mellitus, Type 2; Dose-Response Relation | 1997 |
American Diabetes Association Annual Meeting, 1997. Type 2 diabetes.
Topics: Chromans; Diabetes Mellitus; Diabetes Mellitus, Type 2; Homeostasis; Humans; Hypoglycemic Agents; So | 1997 |
High glucose-induced growth factor resistance in human fibroblasts can be reversed by antioxidants and protein kinase C-inhibitors.
Topics: Antioxidants; Cell Division; Cells, Cultured; Chromans; Diabetes Mellitus; Dose-Response Relationshi | 1997 |
Novel benzoxazole 2,4-thiazolidinediones as potent hypoglycemic agents. Synthesis and structure-activity relationships.
Topics: Animals; Benzopyrans; Benzoxazoles; Chromans; Diabetes Mellitus; Diabetes Mellitus, Type 2; Hypoglyc | 1997 |
Diabetes drug withdrawn after reports of hepatic events.
Topics: Chromans; Diabetes Mellitus; Humans; Hypoglycemic Agents; Legislation, Drug; Thiazoles; Thiazolidine | 1997 |
Fatty acid-induced beta cell apoptosis: a link between obesity and diabetes.
Topics: Animals; Apoptosis; Cells, Cultured; Ceramides; Chromans; Coenzyme A Ligases; Diabetes Mellitus; Dia | 1998 |
Hepatic dysfunction associated with troglitazone.
Topics: Alanine Transaminase; Chemical and Drug Induced Liver Injury; Chromans; Diabetes Mellitus; Female; H | 1998 |
Troglitazone regulation of glucose metabolism in human skeletal muscle cultures from obese type II diabetic subjects.
Topics: Adult; Cells, Cultured; Chromans; Diabetes Mellitus; Diabetes Mellitus, Type 2; Glucose; Glucose Tra | 1998 |
Possible troglitazone-warfarin interaction.
Topics: Anticoagulants; Blood Coagulation; Chromans; Diabetes Mellitus; Drug Interactions; Humans; Hypoglyce | 1998 |
Cost of Troglitazone therapy.
Topics: Chromans; Cost-Benefit Analysis; Diabetes Mellitus; Humans; Hypoglycemic Agents; Thiazoles; Thiazoli | 1998 |
Troglitazone interferes with gemfibrozil's lipid-lowering action.
Topics: Chromans; Diabetes Mellitus; Drug Interactions; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reduc | 1998 |
Troglitazone ameliorates insulin resistance in a diabetic patient with Prader-Willi syndrome.
Topics: Adolescent; Blood Glucose; Chromans; Diabetes Mellitus; Diabetes Mellitus, Type 1; Glucose Intoleran | 1998 |
A novel method for analysis of nuclear receptor function at natural promoters: peroxisome proliferator-activated receptor gamma agonist actions on aP2 gene expression detected using branched DNA messenger RNA quantitation.
Topics: Adipocytes; Animals; Base Sequence; Carrier Proteins; Cells, Cultured; Chromans; Diabetes Mellitus; | 1999 |
Effect of troglitazone on plasma lipid metabolism and lipoprotein lipase.
Topics: 3T3 Cells; Adipocytes; Aged; Animals; Blood Glucose; Blotting, Northern; Chromans; Diabetes Mellitus | 1999 |
Dehydroepiandrosterone suppresses the elevated hepatic glucose-6-phosphatase and fructose-1,6-bisphosphatase activities in C57BL/Ksj-db/db mice: comparison with troglitazone.
Topics: Androstenedione; Animals; Blood Glucose; Body Composition; Chromans; Dehydroepiandrosterone; Diabete | 1999 |
Troglitazone prevents mitochondrial alterations, beta cell destruction, and diabetes in obese prediabetic rats.
Topics: Animals; Blood Glucose; Body Weight; Chromans; Diabetes Mellitus; Eating; Hypoglycemic Agents; Islet | 1999 |
Troglitazone efficacy in a subject with glucocorticoid-induced diabetes.
Topics: Aged; C-Peptide; Chromans; Diabetes Mellitus; Female; Glucocorticoids; Humans; Hypoglycemic Agents; | 1999 |
Pharmacologic management of diabetes mellitus.
Topics: Carbamates; Chromans; Diabetes Mellitus; Humans; Hypoglycemic Agents; Metformin; Piperidines; Sulfon | 1999 |
Tissue-specific actions of antidiabetic thiazolidinediones on the reduced fatty acid oxidation in skeletal muscle and liver of Zucker diabetic fatty rats.
Topics: Administration, Oral; Animals; Chromans; Diabetes Mellitus; Fatty Acids; Hypoglycemic Agents; Liver; | 2000 |
Effects of peroxisome proliferator-activated receptor-alpha and -gamma agonist, JTT-501, on diabetic complications in Zucker diabetic fatty rats.
Topics: Absorptiometry, Photon; Animals; Body Weight; Bone Density; Bone Diseases, Metabolic; Cataract; Chro | 2000 |
How should patients taking the discontinued diabetes drug troglitazone be managed?
Topics: Alanine Transaminase; Chromans; Diabetes Mellitus; Humans; Hypoglycemic Agents; Liver; Pioglitazone; | 2000 |
Potential interaction between troglitazone and atorvastatin.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Chromans; Diabetes Mellitus; Drug In | 2000 |
Troglitazone prevents and reverses dyslipidemia, insulin secretory defects, and histologic abnormalities in a rat model of naturally occurring obese diabetes.
Topics: Adipose Tissue; Aging; Animals; Blood Glucose; Body Weight; Cholesterol; Chromans; Diabetes Mellitus | 2000 |
Up-regulation of peroxisome proliferator-activated receptors (PPAR-alpha) and PPAR-gamma messenger ribonucleic acid expression in the liver in murine obesity: troglitazone induces expression of PPAR-gamma-responsive adipose tissue-specific genes in the li
Topics: Adipose Tissue; Animals; Blotting, Northern; Chromans; Diabetes Mellitus; Gene Expression Regulation | 2000 |
Troglitazone reduces plasma levels of tumour necrosis factor-alpha in obese patients with type 2 diabetes.
Topics: Blood Glucose; C-Peptide; Chromans; Diabetes Mellitus; Diabetes Mellitus, Type 2; Glycated Hemoglobi | 2000 |
Dehydroepiandrosterone suppresses elevated hepatic glucose-6-phosphatase mRNA level in C57BL/KsJ-db/db mice: comparison with troglitazone.
Topics: Animals; Blood Glucose; Blotting, Northern; Body Weight; Chromans; Dehydroepiandrosterone; Diabetes | 2000 |
Antidiabetic treatment for NASH?
Topics: Animals; CCAAT-Enhancer-Binding Proteins; Chromans; Diabetes Mellitus; DNA-Binding Proteins; Fatty L | 2001 |
Diabetic KKAy mice exhibit increased hepatic PPARgamma1 gene expression and develop hepatic steatosis upon chronic treatment with antidiabetic thiazolidinediones.
Topics: Animals; Chromans; Diabetes Mellitus; Fatty Liver; Gene Expression; Hypoglycemic Agents; Liver; Male | 2001 |
Increased lymphatic lipid transport in genetically diabetic obese rats.
Topics: Animals; Bile Acids and Salts; Body Weight; Carrier Proteins; Chromans; Diabetes Mellitus; Diabetes | 2002 |
A treatment for Mr WP: thiazolidinediones after troglitazone.
Topics: Aged; Animals; Body Mass Index; Chromans; Diabetes Mellitus; Diabetes Mellitus, Type 2; Glycated Hem | 2002 |
[Diabetic dyslipoproteinemia: physiopathological bases and treatment prospects].
Topics: Anticholesteremic Agents; Blood Glucose; Cholesterol, HDL; Cholesterol, LDL; Chromans; Clinical Tria | 2001 |
Troglitazone improves GLUT4 expression in adipose tissue in an animal model of obese type 2 diabetes mellitus.
Topics: Adipose Tissue; Animals; Blood Glucose; Cholesterol; Chromans; Diabetes Mellitus; Diabetes Mellitus, | 2002 |
Characterization of CS-045, a new oral antidiabetic agent, II. Effects on glycemic control and pancreatic islet structure at a late stage of the diabetic syndrome in C57BL/KsJ-db/db mice.
Topics: Administration, Oral; Animals; Blood Glucose; Chromans; Diabetes Mellitus; Glucagon; Hyperglycemia; | 1991 |